logo

For the Inventor, By the Inventor

Telford, PA, United States of America

Malcolm Scott

This inventor holds 4 USPTO granted patents and 2 EPO patents. Top assignee: Janssen Pharmaceutica Nv. Active years: 2006-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Malcolm Scott. Retrieved from https://idiyas.com/inventor/malcolm-scott

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4

% Patents Active = 75.0


Average Co-Inventor Count = 8.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:

goldMedal4 out of 2,100 
 
Janssen Pharmaceutica Nv
 patents

Years Active: 2006-2014

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents
1. 8778956 - Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders (2014-07-15),
2. 8426429 - 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) (2013-04-23),
3. 7582649 - Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders (2009-09-01),
4. 7081463 - Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders (2006-07-25),

Title: The Innovative Contributions of Malcolm Scott

Introduction

Malcolm Scott is a notable inventor based in Telford, PA (US), recognized for his significant contributions to the field of pharmaceuticals. With a total of 4 patents to his name, Scott has focused on developing innovative solutions for various medical conditions.

Latest Patents

Among his latest patents, Scott has developed hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives, which are useful for the treatment of ORL-1 receptor mediated disorders. This invention is directed towards novel compounds that can potentially address significant health issues. Additionally, he has created 2-amino-quinazoline derivatives that serve as inhibitors of β-secretase (BACE). This invention is particularly relevant for the treatment of Alzheimer's disease (AD) and related disorders, showcasing his commitment to addressing critical health challenges.

Career Highlights

Throughout his career, Malcolm Scott has worked with prominent companies such as Janssen Pharmaceutica and Baxter. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Scott has collaborated with esteemed colleagues, including Allen B Reitz and Kathleen A Battista, further enhancing the impact of his work in the field.

Conclusion

Malcolm Scott's innovative patents and collaborations highlight his dedication to advancing medical science. His contributions continue to play a vital role in the development of treatments for serious health conditions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…